spec sheet8 rows
Sabcomeline was SmithKline Beecham's most clinically advanced muscarinic-agonist candidate for Alzheimer's disease, marketed in development under the name Memric, and it made it further than most of its rivals in this slice, all the way to Phase III. It bound all five muscarinic receptor subtypes with similar raw affinity but showed functional selectivity for M1 in both cell assays and animal behavior, reversing delay-induced memory deficits in marmosets and rats at doses well below those that triggered cholinergic side effects. Despite genuinely promising early signals of symptomatic benefit in Alzheimer's patients without provoking overt cholinergic toxicity, the Phase III program ultimately produced disappointing results and SmithKline Beecham shelved it, one more entry in the long list of muscarinic-agonist Alzheimer's drugs that looked good on paper and in monkeys but not in a pivotal trial.
- improved memory performance in preclinical delay-based tasks
- designed to avoid the GI/cardiac side effects of non-selective muscarinic agonists
- reference compound for functionally selective M1 agonist design
- reversed delay-induced deficits in T-maze choice accuracy in rats at doses roughly 10-fold below those causing conditioned taste aversion
- improved performance in marmoset cognitive testing
- reported early clinical signals of symptomatic improvement in Alzheimer's patients at well-tolerated doses
- Improved visual discrimination reversal learning in marmosets at a dose that caused no visible cholinergic effects
- Reversed delay-induced memory deficits in the rat T-maze at roughly a tenth of the aversion threshold
- Reduced working and reference memory errors in rats with excitotoxic lesions of the nucleus basalis and medial septum
- Raised cortical acetylcholine and dopamine efflux in rats, an effect blocked by the M1-preferring antagonist telenzepine
- cholinergic side effects (nausea, sweating) still reported at higher exposures
- no confirmed long-term human safety data; never reached market
- cholinergic side effects (nausea, GI upset) emerged at higher doses, the same limiting factor as other muscarinic agonists
- affected dopamine and muscarinic receptor binding patterns in brain imaging studies at higher exposure
Overview
The furthest any orthosteric muscarinic agonist got in Alzheimer's disease, and the cleanest case study in the difference between functional selectivity and binding selectivity. Called M1-selective throughout its development while binding M3 more tightly than M1 and acting as a partial agonist at cardiac M2.
- Sabcomeline was engineered to be 'functionally selective' for M1 receptors specifically so it would spare the M2/M3 receptors responsible for the GI cramping and slowed heart rate seen with older cholinergic agonists like arecoline.
- Sabcomeline carried the development name Memric before it failed Phase III, a name it never got to use commercially.
- The compound developed under the name Memric as an M1-selective agonist binds human M3 about three times more tightly than it binds M1, and produces bradycardia in mouse atria more potently than carbachol does; its selectivity was functional, arising from low efficacy and tissue receptor reserve, not from where it binds.
- In rat cortical slices sabcomeline did not stimulate the M1 phosphoinositide pathway at all; it blocked the response to carbachol, so in that tissue the M1 agonist behaved as an M1 antagonist.
Mechanism
Sabcomeline was described as a functionally selective M1 partial , and the word functionally carries the whole claim. Its binding is not M1-selective at all: against [3H]QNB at cloned human receptors it sits at 170 nM for M1, 180 nM for M2, 90 nM for M4 and 60 nM for M3, so the tightest binding in the panel is at the subtype responsible for salivation, sweating and gut cramp [1]. What it does have is low intrinsic efficacy, marked by a 22-fold gap between its potency against an radioligand, 14 nM against [3H]oxotremorine-M in rat , and against an radioligand, 310 nM against [3H]QNB; that gap lets tissue receptor reserve rather than affinity decide where it behaves like an agonist [1] [6].
In practice that produced maximal depolarisation of the rat superior cervical ganglion at 300 nM, an M1 effect, alongside submaximal effects on M2-mediated release and M3-mediated ileum contraction [6]. Native tissue told a harsher story: in rat cortical slices sabcomeline did not stimulate phosphoinositide hydrolysis at all and instead blocked the M1-mediated response to carbachol with an apparent pKb of 6.9, while in rat atria it inhibited forskolin-stimulated adenylyl cyclase as effectively as carbachol did [9]. In mouse atria it is an M2 partial outright, producing bradycardia with a pEC50 of 6.7, more potently than carbachol at 5.9 or xanomeline at 5.1 [10].
receptor fingerprint
M1 (CHRM1)Partial agonist
M2 (CHRM2)Partial agonist
M3 (CHRM3)Partial agonist
M4 (CHRM4)Partial agonist
M5 (CHRM5)Partial agonist
Cortical M1 phosphoinositide response, ratAntagonist in rat cortical slices
Safetyrisks and cautions, not medical advice
The animal margin looked good and did not survive contact with the clinic. In marmosets, 0.03 mg/kg orally improved discrimination reversal with no emesis, no face rubbing or licking and no change in blood pressure [4], and in rats the T-maze effect appeared at roughly a tenth of the dose that produced conditioned taste aversion [2]. A direct comparison against the competing agonist talsaclidine, however, found sabcomeline's functional M1 selectivity to be the weaker of the two: it caused bronchoconstriction on its own in anaesthetised guinea pigs, and in the rabbit electroencephalogram central activation and cholinergic side effects appeared in the same dose range rather than in separated ones [9].
In mice it did not activate phosphoinositide hydrolysis in vivo, it inhibited agonist-induced stimulation of that pathway, and it produced non-selective cholinergic effects [10]. The bradycardia risk is mechanistic rather than incidental, because sabcomeline is a partial agonist at cardiac M2 and antagonises carbachol-induced bradycardia with a pKB of 7.48 [10].
History
Sabcomeline was designed at SmithKline Beecham in Harlow, where a methoxy imidoyl nitrile group was introduced as a stable bioisostere for the methyl ester of earlier muscarinic agonists; by the time that chemistry was published in December 1997 the compound was already in phase 3 trials for senile dementia of the Alzheimer type [1]. It carried the development name Memric.
The phase 3 programme did not produce a convincing cognitive effect; a 2001 review from the group developing talsaclidine concluded that neither drug showed convincing improvement of cognitive function in mild to moderate Alzheimer's disease and called for a reassessment of the muscarinic hypothesis itself [9]. A 2010 review of muscarinic agonists in primates and clinical trials records the compound being repositioned by Proximagen Group plc for schizophrenia, on the strength of xanomeline's results in that indication rather than sabcomeline's own results in dementia.
Reputation
The most clinically advanced of the orthosteric muscarinic agonists for Alzheimer's disease and, for that reason, the most instructive failure in the set. It is cited now mainly as the case that separates functional selectivity from binding selectivity: a compound can be called M1-selective on the strength of tissue assays while binding M3 roughly three times more tightly than M1 and acting as an M2 partial agonist in the heart.
Subjective profileweighing the evidence above
A clever piece of receptor-selectivity chemistry that never closed the gap between animal cognition data and a convincing human trial.
Resources
This entry is here for reference.
Research
- 1997first citedDesign of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026…
- 1998most active year3 papers
- 2010most recentCognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials
- 1.Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
- 2.Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze
- 3.Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials
- 4.The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset
- 5.SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors
- 6.In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes
- 7.Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry
- 8.Low-affinity M2 receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M1 receptor agonists sabcomeline and xanomeline
- 9.Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man
- 10.Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
- 11.Counteractive effects of a partial (sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area
11 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is sabcomeline available anywhere?
No. It never advanced past clinical research and was not commercialized; there is no legitimate retail source.
Was sabcomeline the same idea as xanomeline?
Related but distinct. Both are M1-preferring muscarinic agonists from the same 1990s research era; sabcomeline used a different quinuclidine-based chemotype and never advanced as far in development.
How far did sabcomeline get in development?
It reached Phase III clinical trials for Alzheimer's disease, further than most compounds in this class, before being discontinued due to disappointing efficacy results.
What made sabcomeline different from other muscarinic agonists tried in Alzheimer's?
It showed functional selectivity for the M1 receptor even though it bound all five muscarinic subtypes with similar affinity, which in animal testing let it produce cognitive benefits at doses well below its side-effect threshold.
Was sabcomeline actually M1-selective?
Functionally, in some tissues; not in terms of where it binds. Against [3H]QNB at cloned human receptors its affinities run 170 nM at M1, 180 nM at M2, 90 nM at M4 and 60 nM at M3, so it binds M3 most tightly of all. The M1 selectivity people quote came from tissue assays where low intrinsic efficacy plus a large M1 receptor reserve let it look like an agonist at M1 and a weak partial agonist elsewhere. In the heart that arrangement produced bradycardia, and in rat cortical slices it produced M1 blockade rather than M1 activation.
How far did it get in development?
Further than any other muscarinic agonist for Alzheimer's disease. It was in phase 3 trials by late 1997 under the development name Memric. The programme did not deliver convincing cognitive improvement in mild to moderate Alzheimer's disease, and a 2001 review that compared it directly with talsaclidine used the pair of failures to argue for reassessing the muscarinic hypothesis.
Why is sabcomeline still mentioned?
Two reasons. It was repositioned for schizophrenia after xanomeline showed effects on negative and cognitive symptoms in that population, and it remains the standard teaching example of functional selectivity, which is a real and useful concept but a fragile basis for a safety claim; tissue receptor reserve changes between species, tissues and diseases, and selectivity that depends on it changes with them.
How does it compare with the M1 PAMs like TAK-071?
Sabcomeline is what those compounds were designed to improve on. It had to be pushed until it activated M1, and the same molecule that activated M1 also occupied M2 in the heart and M3 in the airways and gut. TAK-071 and VU0486846 bind a separate site and multiply the acetylcholine signal already present, at a deliberately low multiplication factor, so the peripheral receptors never receive enough drive to cause the same trouble. The clinical record so far is consistent with that; the phase 2 crossover trial of TAK-071 produced the same rate of adverse events as placebo.
Adverse effects
- cholinergic side effects (nausea, sweating) still reported at higher exposures
- no confirmed long-term human safety data; never reached market
- cholinergic side effects (nausea, GI upset) emerged at higher doses, the same limiting factor as other muscarinic agonists
- affected dopamine and muscarinic receptor binding patterns in brain imaging studies at higher exposure